Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
CONCLUSIONS: Definitive carboplatin-based chemoRT was equivalent to cisplatin-based therapy and superior to RT alone and RT with concurrent cetuximab. In light of recent results of the RTOG 1016 and De-ESCALaTE trials, our findings suggest that carboplatin-based regimens warrant prospective investigation as an alternative to cisplatin for patients who are not cisplatin candidates.
PMID: 31487677 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Erbitux | Head and Neck Cancer | HNSCC | Hypopharyngeal Cancer | Laryngeal Cancer | Medicare | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma